Download Files:
NIC-0102
SKU
HY-151252-1 mg
Category Reference compound
Tags Immunology/Inflammation;Metabolic Enzyme/Protease, Inflammation/Immunology, NOD-like Receptor (NLR);Proteasome
$145 – $2,200
Products Details
Product Description
– NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β[1].
Web ID
– HY-151252
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C21H25BF2N2O4
References
– [1]Wu X, et al. Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity. J Med Chem. 2022 Sep 5.
CAS Number
– 2806031-94-5
Molecular Weight
– 418.24
Compound Purity
– 98.72
SMILES
– CC(C[C@@H](B(O)O)NC([C@@H](NC(C1=C(C=CC=C1F)F)=O)CC2=CC=CC=C2)=O)C
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– NOD-like Receptor (NLR);Proteasome
Pathway
– Immunology/Inflammation;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.